Trade-Ideas: China Biologic Products (CBPO) Is Today's New Lifetime High Stock
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.
Trade-Ideas LLC identified
(
) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified China Biologic Products as such a stock due to the following factors:
- CBPO has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $8.8 million.
- CBPO has traded 1,888 shares today.
- CBPO is trading at a new lifetime high.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in CBPO with the Ticky from Trade-Ideas. See the FREE profile for CBPO NOW at Trade-Ideas
More details on CBPO:
China Biologic Products, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. CBPO has a PE ratio of 30.8. Currently there are 2 analysts that rate China Biologic Products a buy, no analysts rate it a sell, and none rate it a hold.
The average volume for China Biologic Products has been 89,000 shares per day over the past 30 days. China Biologic has a market cap of $2.1 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.78 and a short float of 0.2% with 0.23 days to cover. Shares are up 26.9% year-to-date as of the close of trading on Wednesday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates China Biologic Products as a
. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, robust revenue growth, notable return on equity and reasonable valuation levels. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.
Highlights from the ratings report include:
- Powered by its strong earnings growth of 50.00% and other important driving factors, this stock has surged by 122.03% over the past year, outperforming the rise in the S&P 500 Index during the same period. Regarding the stock's future course, although almost any stock can fall in a broad market decline, CBPO should continue to move higher despite the fact that it has already enjoyed a very nice gain in the past year.
- CHINA BIOLOGIC PRODUCTS INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, CHINA BIOLOGIC PRODUCTS INC increased its bottom line by earning $2.72 versus $1.95 in the prior year. This year, the market expects an improvement in earnings ($3.35 versus $2.72).
- Despite its growing revenue, the company underperformed as compared with the industry average of 36.4%. Since the same quarter one year prior, revenues rose by 36.1%. Growth in the company's revenue appears to have helped boost the earnings per share.
- The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Biotechnology industry and the overall market, CHINA BIOLOGIC PRODUCTS INC's return on equity significantly exceeds that of both the industry average and the S&P 500.
- You can view the full China Biologic Products Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
null